Effect of parathyroid hormone on cardiac function in rats with cardiomyopathy

Wu,Gang‑Yong; Wu,Ting; Xu,Bai‑Da; Shi,Yi‑Cheng; Cheng,Zhi‑Yuan; Zhang,Xiao; Wang,Xiao; Zong,Gang‑Jun

doi:10.3892/etm.2018.6528

Effect of parathyroid hormone on cardiac function in rats with cardiomyopathy

Authors:
- Gang‑Yong Wu
- Ting Wu
- Bai‑Da Xu
- Yi‑Cheng Shi
- Zhi‑Yuan Cheng
- Xiao Zhang
- Xiao Wang
- Gang‑Jun Zong
View Affiliations

Affiliations: Department of Cardiology, 101 Hospital of PLA, Wuxi Clinical Hospital, Anhui Medical University, Wuxi, Jiangsu 214044, P.R. China
Published online on: July 26, 2018 https://doi.org/10.3892/etm.2018.6528
Pages: 2859-2866
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the role of parathyroid hormone (PTH) in non‑ischemic cardiomyopathy (CM) and its underlying mechanism. A total of 30 Sprague‑Dawley male rats were randomly divided into a control group (n=6) and an experimental group (n=24). To induce CM in the rats of the experimental group, 2 mg/kg Adriamycin (ADR) was administered intraperitoneally with 5 equal injections every third day followed by 5 weekly injections resulting in a cumulative dose of 20 mg/kg. Following establishment of the model, rats in the experimental group were subdivided into a PTH‑untreated CM group that received daily normal saline subcutaneous injections for 7 days and three treated CM groups that received daily subcutaneous injections of 5, 10, or 20 µg/kg of recombinant PTH for 7 days. Rats in the control group accordingly received intraperitoneal and subcutaneous injections of normal saline. Blood sample analysis revealed that B‑type natriuretic peptide (BNP), troponin T, C‑reactive protein (CRP), creatinine and phosphorus concentrations were increased in the PTH‑untreated CM group compared with that in the control group, whereas PTH and calcium concentrations were decreased. Administration of PTH dose‑dependently decreased BNP, CRP, creatinine and phosphorus levels, and increased PTH and calcium levels. Notably, there were significant differences in PTH, BNP, troponin T, CRP, creatinine, calcium, and phosphorus levels among the rats in the five groups (P<0.01). Cardiac ultrasonography results indicated that the left ventricular ejection fraction (LVEF) was significantly decreased in rats treated with ADR compared with the rats from the control group (P<0.01). However, the LVEF gradually recovered with elevated PTH treatment doses. The overall differences of LVEF and left ventricular end‑systolic volume in the five experimental groups were statistically significant (P<0.01). Furthermore, there were dose‑dependent increases in LV mass and left ventricular end‑diastolic volume in PTH‑treated rats; however, the differences between any two groups did not reach statistical significance (P>0.05). Immunohistochemical staining and western blot analysis using an anti‑PTH polyclonal antibody was performed to evaluate the protein expression levels of PTH in myocardial tissues. The mRNA expression levels of PTH and BNP were measured using reverse transcription‑quantitative polymerase chain reaction. The results demonstrated that the mRNA and protein expression levels of PTH in myocardial tissues were significantly decreased in ADR‑treated rats compared with the levels in the control group rats. Injection of recombinant PTH significantly increased PTH expression and reduced BNP expression in dose‑dependent manners (P<0.05). These findings demonstrated that PTH can improve cardiac function in rats with ADR‑induced CM, suggesting a potential therapeutic application for PTH in non‑ischemic CM.

View Figures

View References

1	Wu G, Wang X, Wang X, Jiang H, Wang L, Wang T, Liu J, An D, Cao L, Xia Y and Zong G: Serum parathyroid hormone levels predict discharge and readmission for heart failure. Genet Test Mol Biomarkers. 20:328–334. 2016. View Article : Google Scholar : PubMed/NCBI
2	Altay H and Colkesen Y: Parathyroid hormone and heart failure: Novel biomarker strategy. Endocr Metab Immune Disord Drug Targets. 13:100–104. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kubiak GM, Kolaszko A and Nowalany-Kozielska E: Parathyroid hormone serum concentration in Central European patients with non-ischemic heart failure as a potential marker of disease severity and poor prognosis. Endokrynol Pol. 68:299–305. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ballane GT, Sfeir JG, Dakik HA, Brown EM and El-Hajj Fuleihan G: Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy. Eur J Endocrinol. 166:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
5	Qian J, Colbert MC, Witte D, Kuan CY, Gruenstein E, Osinka H, Lanske B, Kronenberg HM and Clemens TL: Midgestational lethality in mice lacking the Parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology. 144:1053–1061. 2003. View Article : Google Scholar : PubMed/NCBI
6	Monego G, Arena V, Pasquini S, Stigliano E, Fiaccavento R, Leone O, Arpesella G, Potena L, Ranelletti FO, Di Nardo P and Capelli A: Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol. 104:427–434. 2009. View Article : Google Scholar : PubMed/NCBI
7	Zittermann A, Ernst JB, Pilz S, Dreier J, Kuhn J, Knabbe C, Gummert JF, Morshuis M and Milting H: Calciotropic and phosphaturic hormones in end-stage heart failure patients supported by a left-ventricular assist device. PLoS One. 11:e01644592016. View Article : Google Scholar : PubMed/NCBI
8	Choi YH, Cowan DB, Wahlers TC, Hetzer R, Del Nido PJ and Stamm C: Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: Implications for the use of Ca(2+) sensitising inotropes after cardiac surgery. Eur J Cardiothorac Surg. 37:376–383. 2010.PubMed/NCBI
9	Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Lüscher TF, et al: Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 126:1031–1039. 2012. View Article : Google Scholar : PubMed/NCBI
10	Capitanio S, Sambuceti G, Giusti M, Morbelli S, Murialdo G, Garibotto G, Vera L, Ameri P, Repetto B, Naseri M, et al: 1,25-Dihydroxy vitamin D and coronary microvascular function. Eur J Nucl Med Mol Imaging. 40:280–289. 2013. View Article : Google Scholar : PubMed/NCBI
11	Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H and De Luca G: Novara Atherosclerosis Study Group (NAS): Parathyroid hormone levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with acetylsalicylic acid and clopidogrel or ticagrelor. Cardiovasc Ther. 34:209–215. 2016. View Article : Google Scholar : PubMed/NCBI
12	Schreckenberg R, Wenzel S, da Costa Rebelo RM, Röthig A, Meyer R and Schlüter KD: Cell-specific effects of nitric oxide deficiency on parathyroid hormone-related peptide (PTHrP) responsiveness and PTH1 receptor expression in cardiovascular cells. Endocrinology. 150:3735–3741. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang LL, Chen D, Lee J, Gu X, Alaaeddine G, Li J, Wei L and Yu SP: Mobilization of endogenous bone marrow derived endothelial progenitor cells and therapeutic potential of parathyroid hormone after ischemic stroke in mice. PLoS One. 9:e872842014. View Article : Google Scholar : PubMed/NCBI
14	Wang ST, Gao YJ, Duan CC, Li DD, Tian XC, Zhang QL, Guo B and Yue ZP: Effects of PTHrP on expression of MMP9 and MMP13 in sika deer antler chondrocytes. Cell Biol Int. 37:1300–1307. 2013. View Article : Google Scholar : PubMed/NCBI
15	Li S, Zou D, Li C, Meng H, Sui W, Feng S, Cheng T, Zhai Q and Qiu L: Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment. Stem Cell Res Ther. 6:1752015. View Article : Google Scholar : PubMed/NCBI
16	Cusano NE, Rubin MR, Zhang C, Anderson L, Levy E, Costa AG, Irani D and Bilezikian JP: Parathyroid hormone 1–84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism. J Clin Endocrinol Metab. 99:E2025–E2028. 2014. View Article : Google Scholar : PubMed/NCBI
17	Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Steinbeck G and Franz WM: Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: Final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol. 48:1712–1721. 2006. View Article : Google Scholar : PubMed/NCBI
18	Zohlnhöfer D, Ott I, Mehilli J, Schömig K, Michalk F, Ibrahim T, Meisetschläger G, von Wedel J, Bollwein H, Seyfarth M, et al: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. JAMA. 295:1003–1010. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zaruba MM, Huber BC, Brunner S, Deindl E, David R, Fischer R, Assmann G, Herbach N, Grundmann S, Wanke R, et al: Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res. 77:722–731. 2008. View Article : Google Scholar : PubMed/NCBI
20	Brunner S, Weinberger T, Huber BC, Segeth A, Zaruba MM, Theiss HD, Assmann G, Herbach N, Wanke R, Mueller-Hoecker J and Franz WM: The cardioprotective effects of parathyroid hormone are independent of endogenous granulocyte-colony stimulating factor release. Cardiovasc Res. 93:330–339. 2012. View Article : Google Scholar : PubMed/NCBI
21	Teraoka K, Hirano M, Yamaguchi K and Yamashina A: Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail. 2:373–378. 2000. View Article : Google Scholar : PubMed/NCBI
22	Schlüter KD and Piper HM: Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 37:34–41. 1998. View Article : Google Scholar : PubMed/NCBI
23	Noda M, Katoh T, Takuwa N, Kumada M, Kurokawa K and Takuwa Y: Synergistic stimulation of parathyroid hormone-related peptide gene expression by mechanical stretch and angiotensin II in rat aortic smooth muscle cells. J Biol Chem. 269:17911–17917. 1994.PubMed/NCBI
24	Wu P, Xie F, Xue M, Xu X, He S, Lin M and Bai L: Advanced oxidation protein products decrease the expression of calcium transport channels in small intestinal epithelium via the p44/42 MAPK signaling pathway. Eur J Cell Biol. 94:190–203. 2015. View Article : Google Scholar : PubMed/NCBI
25	Selim AA, Mahon M, Juppner H, Bringhurst FR and Divieti P: Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling. Am J Physiol Cell Physiol. 291:C114–C121. 2006. View Article : Google Scholar : PubMed/NCBI
26	Hagström E, Ahlström T, Ärnlöv J, Larsson A, Melhus H, Hellman P and Lind L: Parathyroid hormone and calcium are independently associated with subclinical vascular disease in a community-based cohort. Atherosclerosis. 238:420–426. 2015. View Article : Google Scholar : PubMed/NCBI
27	Rocha-Singh KJ, Zeller T and Jaff MR: Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 83:E212–E220. 2014. View Article : Google Scholar : PubMed/NCBI
28	Seeland U, Selejan S, Engelhardt S, Müller P, Lohse MJ and Böhm M: Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res Cardiol. 102:183–193. 2007. View Article : Google Scholar : PubMed/NCBI
29	Hong ZR, Gil HW, Yang JO, Lee EY, Ahn JO and Hong SY: Associations between sympathetic activity, plasma concentrations of renin, aldosterone, and parathyroid hormone, and the degree of intractability of blood pressure control in modialysis patients. J Korean Med Sci. 22:604–610. 2007. View Article : Google Scholar : PubMed/NCBI
30	Cheng ZY, Ye T, Ling QY, Wu T, Wu GY and Zong GJ: Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-κB signaling pathways. Exp Ther Med. 15:1754–1760. 2018.PubMed/NCBI